Resocortol butyrate | 76738-96-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Resocortol butyrate
• 英文别名: [(8S,9S,10R,11S,13S,14S,17R)-11-hydroxy-10,13-dimethyl-3-oxo-17-propanoyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] butanoate
• CAS: 76738-96-0
• 化学式: C₂₆H₃₈O₅
• 分子量: 430.6
• InChiKey: NYLJGSLNIOEAHY-FZNHGJLXSA-N

物化性质

• 沸点：
  559.5±50.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  80.7
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Method and use for increasing efficacy of anti-adhesive compositions in controlling inflammation and pain
  申请人：Warsaw Orthopedic, Inc.

  公开号：EP2465513A2

  公开（公告）日：2012-06-20

  The invention discloses a method and kit thereof for increasing the efficiency of anti-adhesive compositions by parenterally administering a composition comprising an effective amount of at least one pharmaceutically-acceptable anti-adhesive non-ionic polymer to a site of injury, controlling inflammation at the site of injury, and reducing pain.

  本发明公开了一种方法及其试剂盒，可通过肠外给药将包含有效量的至少一种药学上可接受的抗粘连非离子聚合物的组合物用于损伤部位，从而提高抗粘连组合物的效率，控制损伤部位的炎症并减轻疼痛。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
• Corticosteroid containing foam compositions and method of manufacture thereof
  申请人：MAYNE PHARMA LLC

  公开号：US11020407B2

  公开（公告）日：2021-06-01

  The present invention provides a method for treating various skin diseases by topically administering to a subject a composition formulated as a foamable composition which includes a corticosteroid, such as halobetasol. The composition may include a corticosteroid, ethyl alcohol, emulsifying wax, cetostearyl alcohol, polyoxyl 20 cetostearyl ether, water, benzoic acid and propellant.

  本发明提供了一种治疗各种皮肤病的方法，方法是向受试者局部施用配制成可发泡的组合物，该组合物包括皮质类固醇，如卤贝他索。该组合物可包括皮质类固醇、乙醇、乳化蜡、鲸蜡硬脂醇、聚氧乙烯 20 鲸蜡硬脂醚、水、苯甲酸和推进剂。
• LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY
  申请人：Scidose, Llc

  公开号：EP1954244A1

  公开（公告）日：2008-08-13
• METHOD AND USE FOR INCREASING EFFICACY OF ANTI-ADHESIVE COMPOSITIONS IN CONTROLLING INFLAMMATION AND PAIN
  申请人：Warsaw Orthopedic, Inc.

  公开号：EP2104505B1

  公开（公告）日：2014-05-21